Accumulation of amyloid beta (Aβ) is one of the pathological hallmarks of Alzheimer’s disease (AD), which can be visualized using [18F]florbetapir positron emission tomography (PET). The aim of this study was to evaluate various parametric methods and to assess their test-retest (TRT) reliability. Two 90 min dynamic [18F]florbetapir PET scans, including arterial sampling, were acquired (n = 8 AD patient, n = 8 controls). The following parametric methods were used; (reference:cerebellum); Logan and spectral analysis (SA), receptor parametric mapping (RPM), simplified reference tissue model2 (SRTM2), reference Logan (rLogan) and standardized uptake value ratios (SUVr(50–70)). BPND+1, DVR, VT and SUVr were compared with corresponding estimates...
Amyloid positron emission tomography (PET) imaging with florbetapir F (F-AV-45) allows assessment o...
ImportanceThe applicability of β-amyloid peptide (Aβ) positron emission tomography (PET) as a biomar...
Abstract Optimal pharmacokinetic models for quantifying amyloid beta (Aβ) burden using both [18F]fl...
Accumulation of amyloid beta (A beta) is one of the pathological hallmarks of Alzheimer's disease (A...
Accumulation of amyloid beta (A beta) is one of the pathological hallmarks of Alzheimer's disease (A...
The aim of this study was to investigate the test–retest (TRT) repeatability of various parametric q...
Accumulation of amyloid beta can be visualized using [F-18]florbetapir positron emission tomography....
Accumulation of amyloid beta can be visualized using [18F]florbetapir positron emission tomography. ...
Accumulation of amyloid beta can be visualized using [F-18]florbetapir positron emission tomography....
[11C]UCB-J is a PET radioligand that binds to the presynaptic vesicle glycoprotein 2A. Therefore, [1...
International audiencePURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has ...
[18F]Flortaucipir is a PET tau tracer used to visualize tau binding in Alzheimer’s disease (AD) in v...
Optimal pharmacokinetic models for quantifying amyloid beta (Aβ) burden using both [18F]flutemetamol...
Objective: To evaluate the performance characteristics of florbetapir F18 positron emission tomograp...
Amyloid positron emission tomography (PET) imaging with florbetapir F (F-AV-45) allows assessment o...
ImportanceThe applicability of β-amyloid peptide (Aβ) positron emission tomography (PET) as a biomar...
Abstract Optimal pharmacokinetic models for quantifying amyloid beta (Aβ) burden using both [18F]fl...
Accumulation of amyloid beta (A beta) is one of the pathological hallmarks of Alzheimer's disease (A...
Accumulation of amyloid beta (A beta) is one of the pathological hallmarks of Alzheimer's disease (A...
The aim of this study was to investigate the test–retest (TRT) repeatability of various parametric q...
Accumulation of amyloid beta can be visualized using [F-18]florbetapir positron emission tomography....
Accumulation of amyloid beta can be visualized using [18F]florbetapir positron emission tomography. ...
Accumulation of amyloid beta can be visualized using [F-18]florbetapir positron emission tomography....
[11C]UCB-J is a PET radioligand that binds to the presynaptic vesicle glycoprotein 2A. Therefore, [1...
International audiencePURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has ...
[18F]Flortaucipir is a PET tau tracer used to visualize tau binding in Alzheimer’s disease (AD) in v...
Optimal pharmacokinetic models for quantifying amyloid beta (Aβ) burden using both [18F]flutemetamol...
Objective: To evaluate the performance characteristics of florbetapir F18 positron emission tomograp...
Amyloid positron emission tomography (PET) imaging with florbetapir F (F-AV-45) allows assessment o...
ImportanceThe applicability of β-amyloid peptide (Aβ) positron emission tomography (PET) as a biomar...
Abstract Optimal pharmacokinetic models for quantifying amyloid beta (Aβ) burden using both [18F]fl...